Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in District of Columbia: - Kaiser Permanente-Capitol Hill Medical Center — Washington D.C., District of Columbia
Phase 3 Recruiting NIH
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04181060
Sites in District of Columbia: - George Washington University Medical Center — Washington D.C., District of Columbia
Phase 2, Phase 3 Recruiting Industry
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in District of Columbia: - Local Institution - 007-5476 — Washington D.C., District of Columbia
Phase 3 Recruiting Industry
The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-smal…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06077760
Sites in District of Columbia: - George Washington University Medical Faculty Associates ( Site 4064) — Washington D.C., District of Columbia
Phase 3 Recruiting Industry
The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced o…
Sponsor: AstraZeneca
NCT ID: NCT06350097
Sites in District of Columbia: - Research Site — Washington D.C., District of Columbia
Phase 3 Recruiting Industry
This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of meta…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06422143
Sites in District of Columbia: - Washington Hospital Center ( Site 0037) — Washington D.C., District of Columbia
Phase 3 Recruiting Industry
The purpose of this phase 3 multicenter double-blind randomized study is to assess the use of taletrectinib in the early-stage non-small cell lung cancer (NSCLC). The study compares taletrectinib (study drug) versus placebo (sugar pill) in…
Sponsor: Nuvation Bio Inc.
NCT ID: NCT07154706
Sites in District of Columbia: - Georgetown University Medical Cener (GUMC) — Washington D.C., District of Columbia
Phase 3 Recruiting Academic/Other
Primary Objective To compare two smoking cessation interventions among individuals undergoing lung cancer screening. Primary outcomes are: 3-month self-reported abstinence from cigarettes and 6-month self-reported and bioverified abstinenc…
Sponsor: Georgetown University
NCT ID: NCT06290869
Sites in District of Columbia: - Georgetown University Medical Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in District of Columbia: - Washington Cancer Institute at MedStar Washington Hospital Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each othe…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06162221
Sites in District of Columbia: - Georgetown University Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Industry
The main objective of the study is to characterize safety and efficacy of 2 dose levels of anvumetostat by investigator, and to evaluate anvumetostat monotherapy efficacy by Blinded Independent Central Review (BICR).
Sponsor: Amgen
NCT ID: NCT06593522
Sites in District of Columbia: - Medstar Georgetown University Hospital — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy…
Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT07038343
Sites in District of Columbia: - Avenzo Therapeutics Recruiting Site — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alteration. The main purpose of this study is to determine the safety, tolerability, and effectiveness of REGN5093. The study has two phases…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT04077099
Sites in District of Columbia: - Georgetown University Medical Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it is therefore designed as a matrix study. This study aims to assess the a…
Sponsor: EMD Serono Research & Development Institute, Inc.
NCT ID: NCT06710132
Sites in District of Columbia: - Georgetown University - Lombardi Comprehensive Cancer Center - 1134847 — Washington D.C., District of Columbia
Phase 2 Recruiting Federal
This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.
Sponsor: VA Office of Research and Development
NCT ID: NCT06275360
Sites in District of Columbia: - VA Central Office, Washington, DC — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
The goal of this clinical trial is to learn about neoadjuvant cemiplimab with histology-specific chemotherapy followed by resection and adjuvant cemiplimab in stage 3 non-small cell lung cancer (NSCLC) with contralateral mediastinal or ips…
Sponsor: Georgetown University
NCT ID: NCT06449313
Sites in District of Columbia: - Lombardi Comprehensive Cancer Center, Georgetown University — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
This clinical trial plans to assess to what extent the on-treatment circulating tumor DNA (ctDNA) can predict the subset of patients with NSCLC who will respond to immunotherapy treatment only and which patients will need both immunotherap…
Sponsor: Hackensack Meridian Health
NCT ID: NCT05715229
Sites in District of Columbia: - Lombardi Comprehensive Cancer Center, Georgetown University — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untreated ES-SCLC to determine the safety an…
Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
NCT ID: NCT07407933
Sites in District of Columbia: - Site 1001 — Washington D.C., District of Columbia
Phase 1 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. This study is seeking participants who have…
Sponsor: Pfizer
NCT ID: NCT06447662
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia
Phase 1 Recruiting Industry
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The s…
Sponsor: Eli Lilly and Company
NCT ID: NCT06586515
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia
Phase 1 Recruiting Industry
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumo…
Sponsor: Exelixis
NCT ID: NCT06545331
Sites in District of Columbia: - Exelixis Clinical Site #10 — Washington D.C., District of Columbia
Phase 1 Recruiting Academic/Other
This phase I trial is studying the safety, side effects, and best dose of gilteritinib in treating patients with stage IV ALK positive non-small cell lung cancer (NSCLC) who have progressed on other treatments. While there are many approve…
Sponsor: University of Michigan Rogel Cancer Center
NCT ID: NCT06225427
Sites in District of Columbia: - Georgetown University — Washington D.C., District of Columbia
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
Recruiting Academic/Other
This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable) or is …
Sponsor: University of Rochester
NCT ID: NCT06073431
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
Recruiting Academic/Other
This study will evaluate if a direct-to-patient, de-centralized, remote approach will improve clinical research outreach and engagement for patients with SCLC, in the context of a bio-specimen collection study. The study will also assess s…
Sponsor: Addario Lung Cancer Medical Institute
NCT ID: NCT06486428
Sites in District of Columbia: - Https://Alcmi.Org/Clinical-Trials/Current-Studies/Succeed-Study.Html — Multiple Locations, District of Columbia